Sanofi $SNY Shares Sold by Cullen Capital Management LLC

Cullen Capital Management LLC trimmed its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 36.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 393,743 shares of the company’s stock after selling 221,850 shares during the period. Cullen Capital Management LLC’s holdings in Sanofi were worth $16,234,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ritholtz Wealth Management lifted its holdings in shares of Sanofi by 48.3% in the third quarter. Ritholtz Wealth Management now owns 45,685 shares of the company’s stock valued at $1,884,000 after purchasing an additional 14,880 shares in the last quarter. Tidal Investments LLC boosted its position in shares of Sanofi by 21.5% in the second quarter. Tidal Investments LLC now owns 165,289 shares of the company’s stock worth $7,051,000 after buying an additional 29,283 shares during the period. Mondrian Investment Partners LTD grew its holdings in shares of Sanofi by 2.3% during the third quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock valued at $233,038,000 after buying an additional 129,575 shares in the last quarter. Archford Capital Strategies LLC purchased a new position in shares of Sanofi during the second quarter valued at $1,417,000. Finally, Leo Wealth LLC purchased a new position in shares of Sanofi during the third quarter valued at $1,033,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SNY. UBS Group reissued a “neutral” rating on shares of Sanofi in a research note on Thursday, September 17th. DZ Bank restated a “buy” rating on shares of Sanofi in a research report on Friday, July 31st. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. HSBC reiterated a “buy” rating on shares of Sanofi in a report on Thursday, September 10th. Finally, Wolfe Research started coverage on Sanofi in a report on Friday, October 9th. They issued a “peer perform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat, Sanofi presently has a consensus rating of “Hold” and an average price target of $53.00.

View Our Latest Research Report on Sanofi

Sanofi Stock Up 0.0%

SNY stock opened at $48.39 on Tuesday. The company has a 50 day moving average of $42.76 and a two-hundred day moving average of $44.39. The company has a market cap of $117.32 billion, a price-to-earnings ratio of 23.96, a PEG ratio of 1.33 and a beta of 0.31. Sanofi has a 12-month low of $39.07 and a 12-month high of $52.67. The company has a quick ratio of 0.27, a current ratio of 1.12 and a debt-to-equity ratio of 0.20.

Sanofi (NASDAQ:SNY – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.56 by $0.48. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The business had revenue of $17.25 billion for the quarter, compared to analysts’ expectations of $14.30 billion. During the same period in the previous year, the company posted $2.91 EPS. Sanofi’s revenue was up 16.2% on a year-over-year basis. On average, equities analysts anticipate that Sanofi will post 5.07 earnings per share for the current fiscal year.

Sanofi Profile

(Free Report)

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.

Recommended Stories

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.